FluoGuide gets green light to proceed to second dose level with FG001 in the ongoing clinical phase I/II trial in patients with high grade glioma
Copenhagen, Denmark, 17 December 2020 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to announce that the dose escalation committee has approved that administration of the second dose level can now be initiated in the ongoing trial evaluating safety and effcicacy of FG001 in patients with high grade glioma undergoing neurosurgery.Evaluation of the results from the first dose level of FG001, including data from three patients, has been finalized and reported to the dose escalation committee. The dose escalation committee has earlier today been given green light to proceed and